Spero Therapeutics, Inc. (SPRO)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
2.74 USD
+0.06
(2.237%)
⇧
(April 17, 2026, 3:39 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:49 p.m. EDT
SPRO presents a mixed opportunity. Short-term traders may consider the recent price movements and upcoming earnings reports as potential catalysts for momentum plays. However, the stock has shown volatility and lacks a strong dividend yield. Long-term investors might see potential in the company's pipeline, especially with upcoming FDA decisions, but the lack of consistent earnings and the current market cap suggest caution. Overall, the stock is more speculative and requires careful risk management. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.047375 |
| AutoARIMA | 0.047380 |
| AutoETS | 0.047479 |
| MSTL | 0.049702 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 55% |
| H-stat | 2.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.228 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.905 |
| Revenue per Share | 1.192 |
| Market Cap | 158,622,688 |
| Trailing P/E | 18.27 |
| Forward P/E | -2.47 |
| Beta | 1.45 |
| Profit Margins | 12.83% |
| Website | https://sperotherapeutics.com |
As of April 11, 2026, 2:49 p.m. EDT: Options speculators are showing mixed signals. The calls are heavily weighted towards the ATM strike of 2.5, indicating some confidence in the stock staying near this level. However, there is significant OTM call activity, particularly at the 5.0 strike, suggesting some speculation on a potential sharp upward move. Puts are also showing some activity, especially at the 2.0 strike, indicating some bearish sentiment. The overall volatility is relatively low, but there is a notable increase in IV for certain strikes, which could indicate increased uncertainty or anticipation of upcoming events.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.6965518 |
| Address1 | 675 Massachusetts Avenue |
| Address2 | 14th Floor |
| All Time High | 23.639 |
| All Time Low | 0.505 |
| Ask | 2.77 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 551,520 |
| Average Daily Volume3 Month | 366,470 |
| Average Volume | 366,470 |
| Average Volume10Days | 551,520 |
| Beta | 1.45 |
| Bid | 1.96 |
| Bid Size | 2 |
| Book Value | 1.046 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.74 |
| Current Ratio | 7.588 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.78 |
| Day Low | 2.65 |
| Debt To Equity | 4.905 |
| Display Name | Spero Therapeutics |
| Earnings Call Timestamp End | 1,755,030,600 |
| Earnings Call Timestamp Start | 1,755,030,600 |
| Earnings Timestamp | 1,774,555,200 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | 7,161,000 |
| Ebitda Margins | 0.107200004 |
| Enterprise To Ebitda | 16.447 |
| Enterprise To Revenue | 1.763 |
| Enterprise Value | 117,779,200 |
| Eps Forward | -1.11 |
| Eps Trailing Twelve Months | 0.15 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.424 |
| Fifty Day Average Change | 0.31599998 |
| Fifty Day Average Change Percent | 0.13036303 |
| Fifty Two Week Change Percent | 269.65518 |
| Fifty Two Week High | 3.22 |
| Fifty Two Week High Change | -0.48000002 |
| Fifty Two Week High Change Percent | -0.14906833 |
| Fifty Two Week Low | 0.57 |
| Fifty Two Week Low Change | 2.17 |
| Fifty Two Week Low Change Percent | 3.8070178 |
| Fifty Two Week Range | 0.57 - 3.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,509,629,400,000 |
| Float Shares | 47,330,927 |
| Forward Eps | -1.11 |
| Forward P E | -2.4684684 |
| Free Cashflow | -4,250,625 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.42416 |
| Gross Profits | 28,335,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22564 |
| Held Percent Institutions | 0.16927 |
| Implied Shares Outstanding | 57,891,493 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Spero Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 158,622,688 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_240573619 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 8,572,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 155,149,201 |
| Number Of Analyst Opinions | 1 |
| Open | 2.73 |
| Operating Cashflow | -12,624,000 |
| Operating Margins | 0.76047 |
| Payout Ratio | 0.0 |
| Phone | 857 242 1600 |
| Previous Close | 2.68 |
| Price Hint | 4 |
| Price To Book | 2.6195028 |
| Price To Sales Trailing12 Months | 2.37452 |
| Profit Margins | 0.12832 |
| Quick Ratio | 7.403 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.059999943 |
| Regular Market Change Percent | 2.2372177 |
| Regular Market Day High | 2.78 |
| Regular Market Day Low | 2.65 |
| Regular Market Day Range | 2.65 - 2.78 |
| Regular Market Open | 2.73 |
| Regular Market Previous Close | 2.68 |
| Regular Market Price | 2.74 |
| Regular Market Time | 1,776,454,761 |
| Regular Market Volume | 299,150 |
| Return On Assets | 0.04986 |
| Return On Equity | 0.16305 |
| Revenue Growth | 1.745 |
| Revenue Per Share | 1.192 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,891,493 |
| Shares Percent Shares Out | 0.0105 |
| Shares Short | 605,311 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 574,027 |
| Short Name | Spero Therapeutics, Inc. |
| Short Percent Of Float | 0.0127 |
| Short Ratio | 1.88 |
| Source Interval | 15 |
| State | MA |
| Symbol | SPRO |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 40,265,000 |
| Total Cash Per Share | 0.696 |
| Total Debt | 2,895,000 |
| Total Revenue | 66,802,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.15 |
| Trailing P E | 18.266666 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.316425 |
| Two Hundred Day Average Change | 0.42357492 |
| Two Hundred Day Average Change Percent | 0.18285717 |
| Type Disp | Equity |
| Volume | 299,150 |
| Website | https://sperotherapeutics.com |
| Zip | 2,139 |